JP7667773B2 - カンジダ属に対する抗体およびその使用法 - Google Patents

カンジダ属に対する抗体およびその使用法 Download PDF

Info

Publication number
JP7667773B2
JP7667773B2 JP2022506413A JP2022506413A JP7667773B2 JP 7667773 B2 JP7667773 B2 JP 7667773B2 JP 2022506413 A JP2022506413 A JP 2022506413A JP 2022506413 A JP2022506413 A JP 2022506413A JP 7667773 B2 JP7667773 B2 JP 7667773B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
antibody fragment
sequences
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542699A5 (https=
JP2022542699A (ja
JPWO2021021830A5 (https=
Inventor
ラッセル ビー． ウィルソン
ホン シン
ジェームズ イー． ロビンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of JP2022542699A publication Critical patent/JP2022542699A/ja
Publication of JP2022542699A5 publication Critical patent/JP2022542699A5/ja
Publication of JPWO2021021830A5 publication Critical patent/JPWO2021021830A5/ja
Application granted granted Critical
Publication of JP7667773B2 publication Critical patent/JP7667773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022506413A 2019-07-29 2020-07-28 カンジダ属に対する抗体およびその使用法 Active JP7667773B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962879894P 2019-07-29 2019-07-29
US201962879912P 2019-07-29 2019-07-29
US62/879,894 2019-07-29
US62/879,912 2019-07-29
PCT/US2020/043908 WO2021021830A1 (en) 2019-07-29 2020-07-28 Antibodies to candida and uses thereof

Publications (4)

Publication Number Publication Date
JP2022542699A JP2022542699A (ja) 2022-10-06
JP2022542699A5 JP2022542699A5 (https=) 2023-06-20
JPWO2021021830A5 JPWO2021021830A5 (https=) 2023-06-20
JP7667773B2 true JP7667773B2 (ja) 2025-04-23

Family

ID=74230808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506413A Active JP7667773B2 (ja) 2019-07-29 2020-07-28 カンジダ属に対する抗体およびその使用法

Country Status (8)

Country Link
US (1) US20220280618A1 (https=)
EP (1) EP4007772A4 (https=)
JP (1) JP7667773B2 (https=)
KR (1) KR102822827B1 (https=)
CN (1) CN114901688A (https=)
AU (1) AU2020323925A1 (https=)
CA (1) CA3146123A1 (https=)
WO (1) WO2021021830A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991752B (zh) * 2022-12-07 2025-10-31 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用
WO2025090760A1 (en) * 2023-10-25 2025-05-01 Board Of Regents, The University Of Texas System Antibodies specific to scube3 and methods of use
CN119930808B (zh) * 2025-01-09 2025-11-25 普健生物（武汉）科技有限公司 一种抗白念珠菌Csa2蛋白的单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515757A (ja) 2011-04-21 2014-07-03 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 真菌感染症のペプチド及び結合型ワクチン
US20170137476A1 (en) 2014-06-25 2017-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric Vaccine Against Fungal Infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2651575B2 (ja) * 1987-07-13 1997-09-10 神鋼電機株式会社 インバータの過電流検出装置
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
GB0505489D0 (en) * 2005-03-18 2005-04-20 Domantis Ltd Antibodies
EP2102244A2 (en) * 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP3277707A4 (en) * 2015-04-01 2018-08-08 Taipei Medical University Antibodies against infectious diseases
CN108368172B (zh) * 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515757A (ja) 2011-04-21 2014-07-03 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 真菌感染症のペプチド及び結合型ワクチン
US20170137476A1 (en) 2014-06-25 2017-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric Vaccine Against Fungal Infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XIN, H., et al.，"Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis."，VACCINE，2019年03月28日，Vol.37，pp.2430-2438，DOI: 10.1016/j.vaccine.2019.03.061
XIN, H., et al.，"Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis."，CLINICAL AND VACCINE IMMUNOLOGY，2011年10月，Vol.18, No.10，pp.1656-1667，DOI: 10.1128/CVI.05215-11，(EPUB: 10 August 2011)

Also Published As

Publication number Publication date
AU2020323925A1 (en) 2022-03-17
KR20220113346A (ko) 2022-08-12
JP2022542699A (ja) 2022-10-06
KR102822827B1 (ko) 2025-06-19
US20220280618A1 (en) 2022-09-08
EP4007772A4 (en) 2023-11-29
CA3146123A1 (en) 2021-02-04
EP4007772A1 (en) 2022-06-08
CN114901688A (zh) 2022-08-12
WO2021021830A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
JP2023519105A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
JP2023518849A (ja) 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
JP2025106258A (ja) Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
JP7667773B2 (ja) カンジダ属に対する抗体およびその使用法
WO2020061159A1 (en) Human antibodies to zika virus
US20230063625A1 (en) Human antibodies to rift valley fever virus
US20230065377A1 (en) Human antibodies to alphaviruses
US11299535B2 (en) Human IgE antibodies binding to aspergillus allergens
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US20250277015A1 (en) Human monoclonal antibodies to eastern equine encephalitis virus and uses therefor
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
KR20260047586A (ko) 인플루엔자 b 바이러스에 대한 광범위 반응성 항체
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
CN116529259A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220722

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250411

R150 Certificate of patent or registration of utility model

Ref document number: 7667773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150